Beijing Zhong Sheng Heng Yi Pharmaceutical Technology Co., Ltd. Report issue

For profit Phase 1 Phase 2
Founded: Beijing China (2014)

Organization Overview

First Clinical Trial
2019
NCT04188691
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Beijing Zhong Sheng Heng Yi Pharmaceutical Technology Co., Ltd.

Active Ingredients

Drugs in Phase 2 Trials (2)

gi.1/gii.4 bivalent vlp vaccine (2 trials)

recombinant sars-cov-2 vaccine (1 trial)

Drugs in Phase 1 Trials (1)

aluminum hydroxide (Gaviscon) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Caliciviridae Infections (Phase 1)

Gastroenteritis (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 3